[ad_1]
C & Palm Announced Results in '2018 Global Bio Conference & # 39; (GBC2018) Hosted by the Korea Food and Drug Administration
& # 39; Pain-free Cancer Drug & # 39; Cancer drug
A pain-free anti-cancer drug has been developed to treat cancer without causing pain to the patient with the maximum non-toxic dose (NOAEL)
C & PAM (CEO, Chung Hyun-bum) , a biotech company, announced on the 29th that the Korea Food and Drug Administration (KFDA) will host the world's largest bio conference in 2018 (GBC2018) (CP-727) and the results of preclinical testing. have confirmed.
"No pain" anticancer drugs are the least toxic dose of cancer drugs for cancer patients, painless treatment of cancer in the meantime, beyond the maximum non-toxic limit for treatment of pain medications and side effects
He has attracted a lot of attention from domestic and overseas medicines because he overcomes the limitations of existing anti-cancer drugs.
Currently prescribed anti-cancer drugs are administered to patients at doses up to several tens of times the "maximum non-toxic dose". (Nab-Paclitaxel), which is a typical anti-cancer drug used in pancreatic cancer, is administered approximately 40 times the maximum nontoxic dose and approximately 30 times that of Taxol (ingredient name Paclitaxel) used for the treatment of cancer. Ovarian cancer. As a result, cancer patients suffer from various side effects such as neutropenia, platelet loss, weight loss, vomiting, and hair loss.
The new drug, called Pain-free Cancer Drug, overcomes the toxicity and side effects of conventional anti-cancer drugs and induces death of cancer tissue within the maximum non-toxic dose limit
The most important feature is that It allows a treatment against cancer that does not cause pain.
This new drug combines docetaxel and an inorganic polymer, a drug against various cancers such as bad cancer and lung cancer, and its release into the bloodstream is only 3% lower, resulting in little toxicity or toxicity. Side effects. On the other hand, the selectivity (TTR) for cancer tissue by long-term circulation in the body is 10 times higher than in non-cancerous tissues.
The "no pain" anti-cancer drug is supported by the Ministry of Health and Welfare's Health and Medical Technology Research and Development Project and has confirmed its effectiveness and maximum non-toxic Kemon Preclinical Institute, Ewha Womans University, As a result, preliminary mid-term results have already been published in the International Journal of Nanomedicine, SCI, in July last year
Dr. His Yeon-soo, president of the C & Palm Research Institute (chairman of the Korean chemical company, Ewha Womans Univ.) Said: "The pain felt during chemotherapy is due to the toxicity of anticancer drugs. "" No painful anti-cancer drug will open the era of human-centered and patient-centered cancer treatment. "
Pamisel, the commodities drug trade is in full swing …
" Establishing a sustainable growth framework, aiming to enter the growth phase by taking a step "[19659010] Pamisel will launch the new plant of Ulsan Biochemistry to expand its drugstore business
Pamisel announced the construction of a plant with a production capacity of about 500 billion wons a year in the industrial complex of Onsan in Ulsan and the completion ceremony on the 29th of last month.
The company said: "The factory has a size of 7,044 , 29㎡ and has about twice the production capacity compared to the existing plant, "said Lee.Some production lines are running out of supplies to supply Merk, UCB, Nektar, Thermofisher and Sunbao. "
The new factory, created to alleviate the shortage of approvisio owing to the limited production capacity of existing plants and to respond to the increase in the volume of raw material orders, has set up a dedicated production line for mPEGs and nucleosides,
It is described that It is designed to produce material together.
Pamisell's biochemical division invests in the development of high value-added drug intermediates through continuous R & D investments and has been supplying various bioproducts of pharmaceutical companies worldwide for several decades.
The company said it has set up facilities to aggressively pursue the bio-drug market, which has entered its full growth period.
million. Seong Rae Kim said: "The completion of the plant in Ulsan has provided a foundation for continued growth." The goal is to enter a phase of growth in its own right from this year. "
The head office moved to a new building in Seocho-gu, Seoul
[현대건강신문=여혜숙 기자] In order to increase the number of research and development staff, sales and support staff increased Headquarters moved in a new office buildingCELL BIO is a healthcare company equipped with CL mycelium technology and develops CL products in various fields such as the complete treatment of diabetes, the all-in-one cream bar, cosmetics functional, functional foods and biopharmaceuticals.
The all-in-one cream bar contains a large amount of CL mycelium grown by its own technology: it removes fine dust after release, manages the pores of the skin, exfoliates the skin, moisturizes the skin, It is sold very well in Korea and Japan with the nickname "Miracle all-in-one soap" and "Creamy foam soap for the elderly", which is sold at 1~ 20,000 copies each month.
CEL Bio received the Grand Prize for Global Brand Manufacturing and Distribution, the Dong-A Ilbo National Consumer Brand Award, the Luxury Brand Model Awards and the Korea Best Brand Bio Award.
Terae Genteks, the industry's first "genetic counselor", announced that she became the leader in the natural soap industry by purchasing 300,000 pieces of "Rainbow Handy Soap" , a new all-in-one notebook.
Chung Yoon-kyung, Choi Won-na …
[현대건강신문=여혜숙 기자] Terajen Eitex Biotechnology Research Institute said that two researchers have obtained the first certification of "genetic counselor" of the industry.
The genetic counselor provided genetic test results and information on hereditary diseases in patients (patients) and patients with diabetes mellitus.
Qualification of genetic counselor is universalized in overseas countries, but in Korea it is expected that 2015 It was realized for the first time in the year and currently about 30 people in the country have this certificate.
This is the first time that genetic counselors have received this certification from a genomic badysis company.
Terajen Eitelex is a genetic counselor who has a distinctive competitiveness in the field of personalized genome badysis.
It is possible to provide specialized counseling services in the "Direct Direct Genetic Testing (DTC)", which is expected to develop in the market in the future, and to participate in related clinical trials and the academic research
PCEC has reached an agreement with the Ministry of Industry and Trade on the national policy of 10 billion won
[현대건강신문=여혜숙 기자] PCEC signed an agreement with the Ministry of Commerce, of the 'l'; Industry and Energy on Promoting a Promising ProjectThe total period of development is 57 months from April 2018 to December 2022 and the government contribution is 10 billion from won. The project is divided into two stages: for the development of the first phase agreement, the project will run for 33 months until December 31, 2020. The total cost of the project will rise to 8,359 , 2 million won, including the total cost of the project and the private contribution. PCL will develop an integrated transfusion blood test system that incorporates high-risk immunity and blood group testing prior to transfusion through a promising bio-IP company.
In addition, TTDxAS (Total Transfusion Diagnostic Automation System), which is a system that can diagnose it, can be developed by researching HIV, HBV, HCV, HLTV, We will approve clinical features and in multiple global clinics.
This project will shorten the time required to test for HIV, HBV, HCV, HLTV and blood type tests. He should be.
Dr. Kim So-yeon, CEO of PCL, said, "This project is supported only by companies with excellent global skills among companies with patents registered in at least two countries." able to make a successful business because we have been recognized for the ability of PCE to make it more competitive in the global market. "
MSO, etc.
New support service to the management of the company. full hospitality … Establishment of the beachhead for CRO companies
As part of the decision to acquire tangible badets of CYU Healthcare, subsidiary announced on June 18, CU Medical Co., Ltd., said in a statement. The target is the Medical Plaza, which is a building and a workbench Affiliated unit of Namyangju Woori Hospital in Namyangju City, Gyeonggi Province, and includes the site (land).
As a result, the company plans to advance in the company MSO (Hospital Management Support Service), which has been strategically prepared to create future growth engines.
A representative of the company said: "Sales of MSO, which is a new activity, will take place seriously from the second half of this year." "We hope to play a leading role plan in improving the consolidated results of the company.
He added: "From there, we plan to actively establish a bridgehead to enter the CRO business (clinical trials support service) and maximize the competitiveness of the business. business through strategic cooperation with its subsidiary CYU Healthcare. " [19659005]
Development of TiNAL biofab, artificial blood vessel material and 3D printing technology
Selected as a government task based on the technology of the. .. Development objective of 2021
TiNAL Biofab was selected by the Korea Institute of Industrial Technology Assessment and Management (KIDI) as part of the Bio Ink Equipment Development Project for Blood vessels and printing technology of artificial blood vessels using a saturated extracellular matrix.
The consortium was formed with leading research institutes in Korea such as the Catholic University, the National University of Pusan, Pohang University of Science and Technology , and the Korean Institute of Chemical Safety. The period of technological development extends from June to December 31, 2021 and the research team receives about 5.5 billion won from technology development funds during this period.
This project aims to develop materials and technologies to regenerate vascular tissue with the help of human-made cells and 3D printing technology. It solves the side effects such as rejection reaction of existing artificial blood vessels and thrombus formation.
It is expected that this will be an innovative technology to do this.
Through this research and development, TiNAL Biofab will make a total effort to establish the basis for marketed vascular tissue using 3D bio-printing technology.
million. Yun Won-soo, CEO of TiNAL Biofab, said, "By combining various technologies from our company and research institutes, we will conduct research and development activities that meet our expectations and objectives." "We have developed the advanced technology for manufacturing artificial blood vessels. I will help promote the health of patients with diseases. "
Source link
